Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00533-9
Anne-Sophie Darlington PhD, Kirsty Way MSc, Nicole Collaço PhD, Charlotte Cairns MSc, Simone Hanebaum PhD, Silvie H M Janssen PhD, Urška Košir DPhil, Martin G McCabe MD, Daniel Stark MD, Samantha C Sodergren PhD, Winette T A van der Graaf PhD, Olga Husson PhD, STRONG AYA Consortium
Adolescents and young adults aged 15–39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards. A literature review and interviews with adolescents and young adults with cancer and health-care professionals generated a comprehensive list of 129 outcomes, spanning clinical and patient-reported outcomes relevant to adolescents and young adults with cancer. A three-round online Delphi survey involving three stakeholder groups globally, was implemented to reach international consensus. Overall, 262 respondents participated in the Delphi survey and 126 (48·1%) completed three survey rounds. 59 outcomes met consensus in round 3 and were taken forward to the consensus meeting. The final COS consists of 20 outcomes, including two on-treatment specific domains and three off-treatment specific domains. This study developed an adolescents and young adult-specific COS that, when implemented in clinical care and research, will improve the relevance of research findings, enhance care delivery, and enable consistent data synthesis across studies. Future efforts will focus on refining measurement methods and ensuring global applicability.
{"title":"Development of a core outcome set for adolescents and young adults with cancer","authors":"Anne-Sophie Darlington PhD, Kirsty Way MSc, Nicole Collaço PhD, Charlotte Cairns MSc, Simone Hanebaum PhD, Silvie H M Janssen PhD, Urška Košir DPhil, Martin G McCabe MD, Daniel Stark MD, Samantha C Sodergren PhD, Winette T A van der Graaf PhD, Olga Husson PhD, STRONG AYA Consortium","doi":"10.1016/s1470-2045(25)00533-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00533-9","url":null,"abstract":"Adolescents and young adults aged 15–39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards. A literature review and interviews with adolescents and young adults with cancer and health-care professionals generated a comprehensive list of 129 outcomes, spanning clinical and patient-reported outcomes relevant to adolescents and young adults with cancer. A three-round online Delphi survey involving three stakeholder groups globally, was implemented to reach international consensus. Overall, 262 respondents participated in the Delphi survey and 126 (48·1%) completed three survey rounds. 59 outcomes met consensus in round 3 and were taken forward to the consensus meeting. The final COS consists of 20 outcomes, including two on-treatment specific domains and three off-treatment specific domains. This study developed an adolescents and young adult-specific COS that, when implemented in clinical care and research, will improve the relevance of research findings, enhance care delivery, and enable consistent data synthesis across studies. Future efforts will focus on refining measurement methods and ensuring global applicability.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00666-7
Alexander D Sherry, Krishan R Jethwa, Pavlos Msaouel, Ethan B Ludmir
{"title":"The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer","authors":"Alexander D Sherry, Krishan R Jethwa, Pavlos Msaouel, Ethan B Ludmir","doi":"10.1016/s1470-2045(25)00666-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00666-7","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00731-4
Clare Turnbull, Anna Schuh, Richard Sullivan, Paul Pharoah, Matthew E J Callister, Ajay Aggarwal, Stuart Hogarth, Margaret McCartney, Richard Houlston
{"title":"Media coverage and PATHFINDER2: hype, simplification, and free advertising","authors":"Clare Turnbull, Anna Schuh, Richard Sullivan, Paul Pharoah, Matthew E J Callister, Ajay Aggarwal, Stuart Hogarth, Margaret McCartney, Richard Houlston","doi":"10.1016/s1470-2045(25)00731-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00731-4","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00535-2
Prof Ruta Gupta FRCPA, Timothy Fielder FRCPA, Prof Munita Bal MD, Prof Simion I Chiosea MD, Prof Jane E Dahlstrom FRCPA, Aanchal Kakkar MD, Katalin Kiss MD, Prof Jan Laco MD, Neha Mittal MD, Sunil Pasricha MD, Spinder Samra FRCPA, Prof Nina Zidar MD, Prof Martin Bullock MD, Prof Rebecca Chernock MD, Prof William Faquin MD, Prof Mary S Richardson MD, Prof D Neil Hayes MD, Shao Hui Huang MD, Prof Jean Yang PhD, Ziyad Alsugair MD, Nazim Benzerdjeb MD, Shaun Chou FRCPA, Caroline Cooper FRCPA, Katarina Dimnik MD, Rimlee Dutta MD, Prof Ricardo Santiago Gomez PhD, Juan C Hernandez-Prera MD, Meenakshi Kamboj DNB, Tina Klitmøller Agander MD, Ankur Kumar MD, Jenny T H Lee MD, Prof Diana M Bell MD, Prof Toshitaka Nagao MD, Masato Nakaguro MD, Timothy Onyuma FRCPath, Ji Hyun Park MD, Jin Woo Park MD, Asawari Patil MD, Miroslav Podhola MD, Swapnil Rane MD, Sean A Rasmussen MD, Tomáš Rozkoš MD, Prarthna Shah MD, Divakar Sharma MD, Stefi Stefi FRCPA, Antje Stubsgaard MD, Ana Cristina Tetzner DDS, Prof Bruce M Wenig MD, Prof William H Westra MD, Laura Wise FRCPA, Prof Sun Och Yoon MD, HN-CLEAR steering committee and clinical advisory group, Professor Justin A Bishop MD, Professor Keith D Hunter FRCPath, Kelly Magliocca MD, Professor Raja R Seethala MD, Lester D R Thompson MD, Ilan Weinreb MD, Professor Peter Angelos MD, Professor Beth Beadle MD, R Bryan Bell MD, Professor Jonathan R Clark FRACS, Professor Robert Ferris MD, Rahul Ladwa FRACS, James S Lewis Jr MD
Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care.
{"title":"International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative","authors":"Prof Ruta Gupta FRCPA, Timothy Fielder FRCPA, Prof Munita Bal MD, Prof Simion I Chiosea MD, Prof Jane E Dahlstrom FRCPA, Aanchal Kakkar MD, Katalin Kiss MD, Prof Jan Laco MD, Neha Mittal MD, Sunil Pasricha MD, Spinder Samra FRCPA, Prof Nina Zidar MD, Prof Martin Bullock MD, Prof Rebecca Chernock MD, Prof William Faquin MD, Prof Mary S Richardson MD, Prof D Neil Hayes MD, Shao Hui Huang MD, Prof Jean Yang PhD, Ziyad Alsugair MD, Nazim Benzerdjeb MD, Shaun Chou FRCPA, Caroline Cooper FRCPA, Katarina Dimnik MD, Rimlee Dutta MD, Prof Ricardo Santiago Gomez PhD, Juan C Hernandez-Prera MD, Meenakshi Kamboj DNB, Tina Klitmøller Agander MD, Ankur Kumar MD, Jenny T H Lee MD, Prof Diana M Bell MD, Prof Toshitaka Nagao MD, Masato Nakaguro MD, Timothy Onyuma FRCPath, Ji Hyun Park MD, Jin Woo Park MD, Asawari Patil MD, Miroslav Podhola MD, Swapnil Rane MD, Sean A Rasmussen MD, Tomáš Rozkoš MD, Prarthna Shah MD, Divakar Sharma MD, Stefi Stefi FRCPA, Antje Stubsgaard MD, Ana Cristina Tetzner DDS, Prof Bruce M Wenig MD, Prof William H Westra MD, Laura Wise FRCPA, Prof Sun Och Yoon MD, HN-CLEAR steering committee and clinical advisory group, Professor Justin A Bishop MD, Professor Keith D Hunter FRCPath, Kelly Magliocca MD, Professor Raja R Seethala MD, Lester D R Thompson MD, Ilan Weinreb MD, Professor Peter Angelos MD, Professor Beth Beadle MD, R Bryan Bell MD, Professor Jonathan R Clark FRACS, Professor Robert Ferris MD, Rahul Ladwa FRACS, James S Lewis Jr MD","doi":"10.1016/s1470-2045(25)00535-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00535-2","url":null,"abstract":"Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. The histopathologically detected extranodal extension working group established by WHO, International Collaboration on Cancer Reporting, American Joint Committee on Cancer, Union for International Cancer Control, North American Society of Head and Neck Pathology, and American Academy of Oral and Maxillofacial Pathology committees undertook consensus deliberations using scanned whole slides and a PRISMA literature review-based scoping questionnaire. The guidelines were tested by 30 additional pathologists across six continents and strengthened with prescriptive diagnostic criteria and unifying terminology based on the inter-rater concordance analyses. This Review generates practically useful consensus diagnostic recommendations and aligned terminology for addressing the gaps in the histopathologically detected extranodal extension literature. The recommendations can be used globally and cater to all levels of medical resources, practices, and experiences, thus ensuring equitable patient care.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00598-4
Giacomo Montagna MD, Michael Alvarado MD, Sara Myers MD, Mary M Mrdutt MD, Susie X Sun MD, Varadan Sevilimedu DrPH, Andrea V Barrio MD, Astrid Botty van den Bruele MD, Judy C Boughey MD, Marissa K Boyle MD, Angelena Crown MD, Susan B Kesmodel MD, Tari A King MD, Henry M Kuerer MD, Elmore C Leisha MD, Tracy-Ann Moo MD, Anna Weiss MD, Austin D Williams MD, Priyanka Parmar MD, Brian Diskin MD, Callie Hlavin MD, Emilia J Diego MD, Natália Polidorio MD, Khaled Abdelwahab MD, Maggie Banys-Paluchowski MD, Prof Christian Kurzeder MD, Martin Heidinger MD, Maite Goldschmidt MSc, Alexandra Schulz MSc, Prof Jörg Heil MD, Prof Güldeniz Karadeniz Cakmak MD, Nina Pislar MD, Margit Riis MD, Ipshita Prakash MD, Valentina Ovalle MD, M Umit Ugurlu MD, Gianluca Franceschini MD, Emelyanov Alexander Sergeevich MD, Javier Morales MD, Han-Byoel Lee MD, Viviana Galimberti MD, Prof Sung Gwe Ahn MD, Jai Min Ryu MD, Prof Mahmut Muslumanoglu MD, Neslihan Cabıoğlu MD, Tae-Kyung Robyn Yoo MD, Prof Marie-Jeanne Vrancken Peeters MD, Massimo Ferrucci MD, Monica Morrow MD, Prof Walter P Weber MD, microNAC Study Group, Mariacarla Adreozzi PhD, Daniel Meirelles Barbalho MD, Hakan Balbaloglu MD, Prof John Benson MD, Gilles Berclaz MD, Eelco de Bree MD, Jordana de Faria Bessa MD, Eduard-Alexandru Bonci MD, Jana de Boniface MD, Susanne Bucher MD, Jinyoung Byeon MD, Francisco Pimentel Cavalcante MD, Daniela Cocco MD, Prof Fabio Corsi MD, Marcelo Chávez Díaz MD, Alba Di Leone MD, Nina Ditsch MD, Prof Ruth Exner MD, Meghan R Flanagan MD, Prof Maria Luisa Gasparri MD, Mary L Gemignani MD, Eduardo G González MD, Uwe Güth MD, Mehmet Ali Gulcelik MD, Wonshik Han MD, Ruth Helfgott MD, Martin Fernando Rivas Ibarra MD, Justyna Jelinska MD, Michael Knauer MD, Natalia Krawczyk MD, Petr Krivorotko MD, Cornelia Leo MD, Alberto Marchet MD, Prof Jelena Maksimenko MD, Tehillah S Menes MD, Francesco Milardi MD, Hyeong-Gon Moon MD, Olivio Feitosa Costa Neto MD, Valerijus Ostapenko MD, Daniele Passeri MD, Jessica M Pastoriza MD, Régis Paulinelli MD, Andraz Perhavec MD, Ana Car Peterko MD, André Pfob MD, Melissa L Pilewskie MD, David Pinto MD, Thiago Pinto MD, Fiorita Poulakaki MD, Mattea Reinisch MD, Nicola Rocco MD, Isabel T Rubio MD, Omema Saleem MBBS, José Ignacio Sánchez-Méndez MD, Rok Satler MD, Alejandro Martin Sanchez MD, Lorenzo Scardina MD, Freya R Schnabel MD, Christopher Schwartz DO, Jue Li Seah MD, Leonardo Ribeiro Soares MD, Ivan Turčan MD, Cicero Urban MD, Prof Maria Vernet-Tomas MD, Denise Vorburger MD, Sanjay Warrier MD, Kerstin Wimmer MD, Gonzalo Ziegler-Rodriguez MD
Despite the paucity of outcome data, axillary lymph node dissection (ALND) is increasingly being omitted in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy, particularly in those with low-volume residual disease. We investigated oncological outcomes in patients with breast cancer and residual micrometastases in the sentinel lymph nodes treated with or without ALND.
{"title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study","authors":"Giacomo Montagna MD, Michael Alvarado MD, Sara Myers MD, Mary M Mrdutt MD, Susie X Sun MD, Varadan Sevilimedu DrPH, Andrea V Barrio MD, Astrid Botty van den Bruele MD, Judy C Boughey MD, Marissa K Boyle MD, Angelena Crown MD, Susan B Kesmodel MD, Tari A King MD, Henry M Kuerer MD, Elmore C Leisha MD, Tracy-Ann Moo MD, Anna Weiss MD, Austin D Williams MD, Priyanka Parmar MD, Brian Diskin MD, Callie Hlavin MD, Emilia J Diego MD, Natália Polidorio MD, Khaled Abdelwahab MD, Maggie Banys-Paluchowski MD, Prof Christian Kurzeder MD, Martin Heidinger MD, Maite Goldschmidt MSc, Alexandra Schulz MSc, Prof Jörg Heil MD, Prof Güldeniz Karadeniz Cakmak MD, Nina Pislar MD, Margit Riis MD, Ipshita Prakash MD, Valentina Ovalle MD, M Umit Ugurlu MD, Gianluca Franceschini MD, Emelyanov Alexander Sergeevich MD, Javier Morales MD, Han-Byoel Lee MD, Viviana Galimberti MD, Prof Sung Gwe Ahn MD, Jai Min Ryu MD, Prof Mahmut Muslumanoglu MD, Neslihan Cabıoğlu MD, Tae-Kyung Robyn Yoo MD, Prof Marie-Jeanne Vrancken Peeters MD, Massimo Ferrucci MD, Monica Morrow MD, Prof Walter P Weber MD, microNAC Study Group, Mariacarla Adreozzi PhD, Daniel Meirelles Barbalho MD, Hakan Balbaloglu MD, Prof John Benson MD, Gilles Berclaz MD, Eelco de Bree MD, Jordana de Faria Bessa MD, Eduard-Alexandru Bonci MD, Jana de Boniface MD, Susanne Bucher MD, Jinyoung Byeon MD, Francisco Pimentel Cavalcante MD, Daniela Cocco MD, Prof Fabio Corsi MD, Marcelo Chávez Díaz MD, Alba Di Leone MD, Nina Ditsch MD, Prof Ruth Exner MD, Meghan R Flanagan MD, Prof Maria Luisa Gasparri MD, Mary L Gemignani MD, Eduardo G González MD, Uwe Güth MD, Mehmet Ali Gulcelik MD, Wonshik Han MD, Ruth Helfgott MD, Martin Fernando Rivas Ibarra MD, Justyna Jelinska MD, Michael Knauer MD, Natalia Krawczyk MD, Petr Krivorotko MD, Cornelia Leo MD, Alberto Marchet MD, Prof Jelena Maksimenko MD, Tehillah S Menes MD, Francesco Milardi MD, Hyeong-Gon Moon MD, Olivio Feitosa Costa Neto MD, Valerijus Ostapenko MD, Daniele Passeri MD, Jessica M Pastoriza MD, Régis Paulinelli MD, Andraz Perhavec MD, Ana Car Peterko MD, André Pfob MD, Melissa L Pilewskie MD, David Pinto MD, Thiago Pinto MD, Fiorita Poulakaki MD, Mattea Reinisch MD, Nicola Rocco MD, Isabel T Rubio MD, Omema Saleem MBBS, José Ignacio Sánchez-Méndez MD, Rok Satler MD, Alejandro Martin Sanchez MD, Lorenzo Scardina MD, Freya R Schnabel MD, Christopher Schwartz DO, Jue Li Seah MD, Leonardo Ribeiro Soares MD, Ivan Turčan MD, Cicero Urban MD, Prof Maria Vernet-Tomas MD, Denise Vorburger MD, Sanjay Warrier MD, Kerstin Wimmer MD, Gonzalo Ziegler-Rodriguez MD","doi":"10.1016/s1470-2045(25)00598-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00598-4","url":null,"abstract":"Despite the paucity of outcome data, axillary lymph node dissection (ALND) is increasingly being omitted in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy, particularly in those with low-volume residual disease. We investigated oncological outcomes in patients with breast cancer and residual micrometastases in the sentinel lymph nodes treated with or without ALND.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00402-4
Jong-Mu Sun MD, Yee Chao MD, Prof Sung-Bae Kim MD, Sun Young Rha MD, Thomas R Jeffry Evans MD, Andrew H Strickland FRACP, Zev Wainberg MD, Prof Ian Chau MD, Sharon Pelles-Avraham MD, Prof Jaffer Ajani MD, Ritu Malhotra PhD, Qingyuan Liu PhD, Sijing Li PhD, Edward Cha MD, Melania Kalaitzidou PhD, Xiayu Huang PhD, Simon Allen PhD, Prof Chih-Hung Hsu MD
Chemotherapy, with or without immunotherapy, is a standard of care for first-line treatment of locally advanced or metastatic oesophageal cancer. However, outcomes remain poor. We aimed to evaluate the activity and safety of tiragolumab, an anti-TIGIT monoclonal antibody, plus atezolizumab, an anti-PD-L1 monoclonal antibody, and chemotherapy in treatment-naive locally advanced unresectable or metastatic oesophageal cancer.
{"title":"First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial","authors":"Jong-Mu Sun MD, Yee Chao MD, Prof Sung-Bae Kim MD, Sun Young Rha MD, Thomas R Jeffry Evans MD, Andrew H Strickland FRACP, Zev Wainberg MD, Prof Ian Chau MD, Sharon Pelles-Avraham MD, Prof Jaffer Ajani MD, Ritu Malhotra PhD, Qingyuan Liu PhD, Sijing Li PhD, Edward Cha MD, Melania Kalaitzidou PhD, Xiayu Huang PhD, Simon Allen PhD, Prof Chih-Hung Hsu MD","doi":"10.1016/s1470-2045(25)00402-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00402-4","url":null,"abstract":"Chemotherapy, with or without immunotherapy, is a standard of care for first-line treatment of locally advanced or metastatic oesophageal cancer. However, outcomes remain poor. We aimed to evaluate the activity and safety of tiragolumab, an anti-TIGIT monoclonal antibody, plus atezolizumab, an anti-PD-L1 monoclonal antibody, and chemotherapy in treatment-naive locally advanced unresectable or metastatic oesophageal cancer.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：